Omthera Pharmaceuticals (NASDAQ: OMTH) released its earnings data on Tuesday. The company reported ($3.08) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($2.31) by $0.77, Analyst Ratings Network reports.
A number of research firms have also recently commented on OMTH. Analysts at Stifel Nicolaus initiated coverage on shares of Omthera Pharmaceuticals in a research note to investors on Tuesday, May 7th. They set a “buy” rating and a $14.00 price target on the stock. On a related note, analysts at Leerink Swann initiated coverage on shares of Omthera Pharmaceuticals in a research note to investors on Tuesday, May 7th. They set an “outperform” rating on the stock. Finally, analysts at Piper Jaffray initiated coverage on shares of Omthera Pharmaceuticals in a research note to investors on Tuesday, May 7th. They set an “overweight” rating on the stock.
Five investment analysts have rated the stock with a buy rating, Omthera Pharmaceuticals has a consensus rating of “Buy” and an average target price of $12.67.
Omthera Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of new therapies for abnormalities in blood lipids, referred to as dyslipidemia, and the treatment of cardiovascular disease.
